Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice

Hua Zhang, Calvin Q Pan, Qiumei Pang, Ruihua Tian, Miaoe Yan, Xin Liu, Hua Zhang, Calvin Q Pan, Qiumei Pang, Ruihua Tian, Miaoe Yan, Xin Liu

Abstract

Little observational data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mother-to-child transmission (MTCT) in real-world settings. During the period of January 2009 to March 2011, we enrolled hepatitis B e antigen-positive mothers with HBV DNA >6 log10 copies/mL in China. At gestation week 28, the mothers received LdT or LAM until postpartum week 4 or no treatment (NTx). The study endpoints were the safety of LdT/LAM use and MTCT rates. Of the 700 mothers enrolled, 648 (LdT/LAM/NTx=252/51/345) completed the 52-week study with 661 infants (LdT/LAM/NTx=257/52/352). On treatment, viral rebound occurred in 1.6% of mothers, all resulting from medication noncompliance. There was no genotypic mutation detected. At delivery, significantly lower HBV DNA levels were noted in mothers who received LdT or LAM versus NTx. Alanine aminotransferase flares were observed in 17.1% of treated mothers versus 6.3% of untreated mothers (P < 0.001). At birth, hepatitis B surface antigen (HBsAg) was detected in 20% and 24% of newborns in the treated and NTx groups, respectively. At week 52, an intention-to-treat analysis indicated 2.2% (95% confidence [CI]: 0.6-3.8) of HBsAg+ infants from the treated group versus 7.6% (95% CI: 4.9-10.3) in the NTx group (P50.001) and no difference of HBsAg+ rate between infants in the LdT and LAM groups(1.9% vs. 3.7%; P=0.758). On-treatment analysis indicated 0% of HBsAg+ infants in the treated group versus 2.84% in the NTx group (P=0.002). There were no differences for gestational age or infants' height, weight, Apgar scores, or birth defect rates between infants from the treated and untreated groups.

Conclusions: LdT and LAM use in late pregnancy for highly viremic mothers was equally effective in reducing MTCT. The treatment was well tolerated with no safety concerns identified.

Trial registration: ClinicalTrials.gov NCT01743079.

Figures

Fig 1
Fig 1
Disposition of mothers and infants.
Fig 2
Fig 2
MTCT rates among infants born to mothers who received antiviral or no treatment. ITT = Intention-to-treat, analysis performed in all enrolled patients. Patients lost to follow-up during the study were counted as treatment failures (infected cases). On-treatment analysis was defined as analysis performed in patients who completed the 52-week follow-up. Patients who were lost to follow-up or who discontinued the study were excluded.

References

    1. World Health Organization. Hepatitis B fact sheet, July. 2013. Available at: . Accessed November 2013.
    1. Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J, Tong MJ. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2012;10:452–459.
    1. Beasley RP, Hwang LY. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis. 1983;147:185–190.
    1. Centers for Disease Control and Prevention (CDC) Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data—United States. MMWR Morb Mortal Wkly Rep. 2011;60:410–413.
    1. del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WC, Gerards LJ, et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine. 1997;15:1624–1630.
    1. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;19:e18–e25.
    1. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94–103.
    1. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190:489–492.
    1. Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:520–526.
    1. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215–1221.
    1. Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Digest Dis Sci. 2012;57:2423–2429.
    1. Nie R, Jin L, Zhang H, Xu B, Chen W, Zhu G. Presence of hepatitis B virus in oocytes and embryos: a risk of hepatitis B virus transmission during in vitro fertilization. Fertil Steril. 2011;95:1667–1671.
    1. Pan CQ, Hu KQ, Tsai N. Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients. Antivir Ther. 2013;18:841–852.
    1. Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J, Tong MJ. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2012;10:452–459.
    1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
    1. APR. Antiviral Pregnancy Registry Interim report 1 January 1989 through 31 Jnurary 2012. 2012. Available at: . Accessed November.
    1. Pan CQ, Lee HM. Antiviral therapy for chronic hepatitis B in pregnancy. Semin Liver Dis. 2013;33:138–146.
    1. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.
    1. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007;5:890–897.
    1. Margeridon-Thermet S, Svarovskaia ES, Babrzadeh F, Martin R, Liu TF, Pacold M, et al. Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of lamivudine treatment. Antimicrob Agents Chemother. 2013;57:343–349.
    1. Liu M, Cai H, Yi W. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat. 2013;20(Suppl 1):65–70.
    1. Brown RS, Jr, Verna EC, Pereira MR, Tilson HH, Aguilar C, Leu CS, et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol. 2012;57:953–959.

Source: PubMed

3
Tilaa